Misplaced Pages

Myrexis

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Myrexis" – news · newspapers · books · scholar · JSTOR (July 2014) (Learn how and when to remove this message)
The topic of this article may not meet Misplaced Pages's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted.
Find sources: "Myrexis" – news · newspapers · books · scholar · JSTOR (July 2014) (Learn how and when to remove this message)
(Learn how and when to remove this message)

Myrexis is a biopharmaceutical company based in Salt Lake City, Utah, USA. It focused on drug development in several areas of medicine, in particular cancer therapy and auto-immune diseases. It was founded in 1999 as a spin-off from Myriad Genetics and was originally known as Myriad Pharmaceuticals. Richard B. Brewer was its CEO from May 2012 until his death in August 2012.

In February 2012 the company announced they had suspended development activity on all of its clinical and preclinical programs and appointed an investment company Stifel Nicolaus Weisel to evaluate strategic alternatives. In November 2012, the board of Myrexis announced that it planned to put the company into liquidation subject to shareholder approval. In January 2013, the board reversed its decision, cancelled the liquidation, declared a special cash distribution to shareholders and appointed Jonathan M. Couchman (chairman of Xselos Holdings) as president and chief executive officer. The remaining members of the board then resigned.

References

  1. Staff (2 July 2009) "Myriad Pharmaceuticals, Inc. Established As An Independent Pharmaceutical Development Company" Pharmaceutical Online, 2 July 2009. Retrieved 26 July 2014
  2. "Richard Brewer". San Francisco Chronicle. 20 August 2012. Retrieved 25 August 2012.
  3. "Myrexis Announces Death of Chief Executive Officer Richard B. Brewer, Trailblazing Biotechnology Industry Veteran and Patient Advocate". Myrexis. Archived from the original on November 5, 2012. Retrieved 15 August 2012.
  4. Staff. "MYRX.PK - Myrexis Inc Profile | Reuters". Reuters. Retrieved 2021-02-05.
  5. Tadena, Nathalie, "Myrexis Board Approves Plan to Liquidate Assets, Dissolve Company", The Wall Street Journal, 9 November 2012. Retrieved 20 January 2013
  6. Myrexis Inc press release:"Myrexis, Inc. Announces the Cancellation of Its Upcoming Shareholder Meeting", carried by Bloomberg, 23 January 2013. Retrieved 26 July 2014
Categories: